Polysaccharides Patents (Class 536/123.1)
-
Patent number: 8946407Abstract: Provided are a fructosylated mangiferin, a preparation method therefor and a use thereof, wherein the fructosylated mangiferin has a structural formula represented by the following formula (I), the method for preparing the fructosylated mangiferin includes adding a substance with fructosylating enzymatic activity to a transformed liquid containing mangiferin for biotransformation reaction, so as to convert the mangiferin into the fructosylated mangiferin, wherein the transformed liquid contains the mangiferin and a glycosyl donor; as well as a use of the fructosylated mangiferin in preparation of a medicament for treatment of tumor-related diseases.Type: GrantFiled: March 8, 2012Date of Patent: February 3, 2015Assignee: Nanjing University of TechnologyInventors: Bingfang He, Xueming Wu, Jianlin Chu, Bin Wu, Sen Zhang, Pingkai Ouyang
-
Patent number: 8945568Abstract: Disclosed is a new and emerging serotype of Streptococcus pneumoniae designated serotype 6D, and assays and monoclonal antibodies useful in identifying same. Also disclosed is a novel pneumococcal polysaccharide with the repeating unit?2) glucose 1 (1?3) glucose 2 (1?3) rhamnose (1?4) ribitol (5?phosphate. This new serotype may be included in pneumococcal vaccines.Type: GrantFiled: April 19, 2013Date of Patent: February 3, 2015Assignee: The UAB Research FoundationInventors: Moon H. Nahm, In Ho Park
-
Publication number: 20150031532Abstract: The present invention relates to stabilized channel type cyclodextrin crystals. In particular the present invention relates to a method for producing stabilized channel type cyclodextrin crystals, stabilized channel type cyclodextrin crystal comprising a stabilizer, uses of said stabilized crystals and products comprising stabilized channel type cyclodextrin crystals.Type: ApplicationFiled: March 13, 2013Publication date: January 29, 2015Applicant: Amphidex A/SInventors: Kim Lambertsen Larsen, Ronnie Nielsen, Thuy Thanh Do
-
Publication number: 20150025234Abstract: The invention provides novel gangliosides and mixtures of novel gangliosides, and drug products containing the same. The invention also provides cells induced to over-express one or more gangliosides. The invention further provides methods for production of gangliosides, e.g., GM1, from cells in culture using, for example, bone marrow cells and neuroblastoma cells. Methods include the treatment of cells with neural induction media and chloroquine, or chloroquine alone in the case of, e.g., human bone marrow cells, neuraminidase or glucosamine, to induce the production of gangliosides, e.g., GM1, in the cells. Also provided are methods of long-term, high density culturing of cells without passaging to produce gangliosides, e.g., GM1. Methods of quantifying gangliosides, e.g., GM1 in cell culture are also provided.Type: ApplicationFiled: March 14, 2014Publication date: January 22, 2015Inventors: Vanessa RAGAGLIA, Vandana Madanlal Sharma
-
Publication number: 20150017699Abstract: The present invention is generally directed to internally functionalized graphene substrates, methods of making such substrates and methods of using such substrates. In one aspect, the present invention is a graphene substrate. The substrate comprises edge and non-edge regions. Organic or inorganic molecules are bound to the non-edge regions of the substrate, and the organic or inorganic molecules are present on the substrate edges at a population greater than about one molecule per 10,000 nm2.Type: ApplicationFiled: July 9, 2014Publication date: January 15, 2015Applicant: NANOTECH BIOMACHINES, INC.Inventors: Jeffrey Alan McKinney, William Emerson Martinez
-
Patent number: 8933218Abstract: The present application describes a process for conjugating a PNAG which is less than 40% N-acetylated to a carrier protein.Type: GrantFiled: March 29, 2007Date of Patent: January 13, 2015Assignee: GlaxoSmithKline Biologicals s.a.Inventors: Ralph Leon Biemans, Pierre Duvivier, Tomas Maira-Litran
-
Publication number: 20150011748Abstract: A method is for the manufacture of aqueous solutions of alkali metal salt of carboxymethyl fructan. More specifically the method for the manufacture of aqueous solutions includes at least 20% by weight of alkali metal salt of carboxymethyl fructan having a degree of carboxymethyl substitution of at least 1.2.Type: ApplicationFiled: February 7, 2013Publication date: January 8, 2015Applicant: ITALMATCH CHEMICALS SPAInventors: Patrick Pierre Notté, Albert Firmin Devaux
-
Publication number: 20150007953Abstract: A process comprising treating a lignocellulosic material preferably pulp in the presence of a transition metal catalyst with a oxidizing agent selected from a group consisting of hydrogen peroxide, hypochlorite, hypochlorous acid and any combination thereof to form a treated lignocellulosic material having a viscosity equal to or less than about 17 cp and having reducing functional groups selected from the group consisting of aldehyde and aldehyde type functional groups at the C6 and C1 positions but predominating at the C1 position.Type: ApplicationFiled: June 17, 2014Publication date: January 8, 2015Inventors: ZHENG TAN, DAMARIS LORENZONI, GOPAL GOYAL, SEN YANG
-
Patent number: 8927698Abstract: The present invention relates to an improved synthesis of a trisaccharide of the formula, novel intermediates used in the synthesis and the preparation of the intermediates.Type: GrantFiled: April 7, 2010Date of Patent: January 6, 2015Assignee: Glycom A/SInventors: Gyula Dékany, Istvan Bajza, Julien Boutet, Ignacio Pérez Figueroa, Markus Hederos, Ferenc Horvath, Piroska Kovács-Pénzes, Lars Kröger, Johan Olsson, Christoph Röhrig, Andreas Schroven, Ioannis Vrasidas
-
Patent number: 8926985Abstract: The present invention relates to the field of bacterial polysaccharide antigen vaccines. In particular, the present invention relates to bacterial polysaccharides conjugated to protein D from H. influenzae.Type: GrantFiled: November 5, 2009Date of Patent: January 6, 2015Assignee: GlaxoSmithKline Biologicals S AInventors: Carine Capiau, Marguerite Deschamps, Pierre Michel Desmons, Craig Antonyjoseph Laferriere, Jan Poolman, Jean-Paul Prieels
-
Patent number: 8927522Abstract: Provided herein are microalgal polysaccharide compositions and. Also provided are methods of using polysaccharides for applications such as topical personal care products, cosmetics, and wrinkle reduction compositions. The invention also provides novel microalgal compositions useful for improving the health and appearance of skin. The invention also includes insoluble polysaccharide particles for application to human skin.Type: GrantFiled: March 29, 2010Date of Patent: January 6, 2015Assignee: Solazyme, Inc.Inventors: Anna Coragliotti, Scott Franklin, Anthony G. Day, Stephen M. Decker
-
Publication number: 20150004183Abstract: The present invention provides an antitumor agent having high safety, which is a molecular target drug against malignant tumors. An anti-malignant tumor agent characterized by containing, as an active ingredient, a substance targeting ribosomal proteins shows increased expression in malignant tumor cells. The substance of the present inventions targeting the ribosomal protein showing increased expression in the malignant tumor cell may be a substance involved in one of biological defense mechanisms which are considered to be intrinsically provided in a living body and prevent onset of disease even if cancer cells develop. Specifically, the ribosomal protein showing increased expression is RPL29 and/or RPS4X.Type: ApplicationFiled: January 23, 2013Publication date: January 1, 2015Inventors: Yasuhiro Miyake, Kazuhide Yamamoto
-
Patent number: 8921338Abstract: The present specification discloses fluid compositions comprising a matrix polymer and stabilizing component, methods of making such fluid compositions, and methods of treating skin conditions in an individual using such fluid compositions.Type: GrantFiled: November 12, 2013Date of Patent: December 30, 2014Assignee: Allergan Industrie, SASInventor: Pierre F. Lebreton
-
Publication number: 20140378412Abstract: A method comprising administering an oligosaccharide composition to an organism having a gastrointestinal system to affect the production of GHG produced by the organism allowing for a reduction of the GHG produced by the organism while optimizing the health, feed intake, and protein synthesis of the organism so that management of the organism may realize the synergistic effects of maximizing both typical organism commodity-type concerns (e.g., size and production metrics) and atypical organism commodity-type concerns (e.g., carbon credit trading/monetization). A gas-reducing composition comprising soluble extractable material from a lignocellulosic source.Type: ApplicationFiled: August 21, 2014Publication date: December 25, 2014Inventors: Matthew W. Lowe, Anne Chace Hopkins, Thomas A. Lehtinen
-
Patent number: 8916145Abstract: The invention relates to the use, in the manufacture of a medicament or a therapeutic nutritional composition for preventing or reducing inflammation in a mammal, of bifidobacterium longum ATCC BAA-999.Type: GrantFiled: February 14, 2007Date of Patent: December 23, 2014Assignee: Nestec S.A.Inventors: Annick Mercenier, Stephanie Blum-Sperisen, Florence Rochat
-
Patent number: 8916542Abstract: Described herein are methods and compositions using chitosan derivatives to treat and/or inhibit acquisition of multiple drug resistance (MDR). Also described herein are methods and compositions using chitosan derivatives in combination with an antibacterial agent to treat a bacterial infection and/or inhibit growth of bacteria, for example, resulting in a synergistic or sensitizing effect.Type: GrantFiled: November 12, 2009Date of Patent: December 23, 2014Assignee: Synedgen, Inc.Inventors: Shenda Baker, William P. Wiesmann, Stacy Townsend
-
Patent number: 8912165Abstract: A method of treating an ulcer comprising applying to the ulcer a preparation comprising a water-soluble ?-(1,3) glucan with ?-(1,6) linked side-chains, where the side-chains comprise ?-(1,3) linkages or up to four consecutive ?-(1,6) linkages a active ingredients.Type: GrantFiled: July 2, 2013Date of Patent: December 16, 2014Assignee: Biotec Pharmacon ASAInventors: Rolf Engstad, Rolf Seljelid
-
Publication number: 20140364599Abstract: A method is disclosed for the acid-catalyzed oligomerization of monosaccharides and/or disaccharides in which monosaccharides or disaccharides are subjected to a mechanical treatment in the presence of an inorganic and/or organic acid. During said process, a catalytic conversion of the monosaccharides or disaccharides takes place.Type: ApplicationFiled: December 18, 2012Publication date: December 11, 2014Applicant: STUDIENGESELLSCHAFT KOHLE MBHInventors: Ferdi Schüth, Roberto Rinaldi, Niklas Meine
-
Publication number: 20140363463Abstract: A shortened process for producing a solution containing substantially purified capsular polysaccharides from a cellular Streptococcus pneumoniae lysate broth is described. Ultrafiltering and diafiltering a clarified S. pneumoniae lysate followed by pH adjustment to less than 4.5, preferably about 3.5, precipitated at least 98% of the protein in the solution without seriously affecting polysaccharide yield. Furthermore, following ultrafiltration and diafiltration and acidification to a pH of less than 4.5, filtration using activated carbon precipitated at least 90% of remaining protein without seriously affecting polysaccharide yield. Exemplary, non-limiting S. pneumoniae serotypes that can be purified using the shortened process of the invention are 1, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F.Type: ApplicationFiled: January 24, 2014Publication date: December 11, 2014Applicant: Wyeth LLCInventors: Yonghui YUAN, Mark RUPPEN, Wei-Qiang SUN, Ling CHU, John SIMPSON, James PATCH, Justin Keith MORAN, Pamela FINK CHARBONNEAU
-
Patent number: 8906832Abstract: A method, system and device to identify, study and/or mimic carbohydrate-protein interactions on cell surfaces and in solution measured by a glycan microarray. In some instances the method, system and device uses very small quantities of carbohydrate as low as attomol. In some instances the system, method and device is high-throughput. The small quantity sensitivity may allow for close placement of carbohydrate array members wherein due to close proximity multivalent interactions with proteins may be identified.Type: GrantFiled: April 14, 2009Date of Patent: December 9, 2014Assignee: Academia SinicaInventors: Chi-Huey Wong, Pi-Hui Liang
-
Patent number: 8906393Abstract: Polysaccharide-containing extracts isolated from a host cell containing nucleotide sequences encoding genes pamA, pamB and pamC, wherein the extract is capable of inhibiting biofilm formation produced by gram-negative bacteria, gram-positive bacteria and fungi, and methods to inhibit biofilm formation or remove biofilms that have already formed.Type: GrantFiled: January 26, 2012Date of Patent: December 9, 2014Assignee: Rutgers, The State University of New JerseyInventors: Jeffrey B. Kaplan, Nataliya V. Balashova, Scott C. Kachlany, Evguenii Vinogradov
-
Patent number: 8901092Abstract: Embodiments of the invention include functionalized polysaccharides and compositions and structures including the same. In an embodiment, the invention includes an active agent delivery composition including a polysaccharide functionalized with a coupling group, wherein the polysaccharide lacks charged groups at a pH of between 6 and 8; and a complex comprising a nucleic acid and a transfection agent. In an embodiment, the invention includes an active agent delivery structure including a matrix comprising a polysaccharide covalently cross-linked through the residue of a coupling group on the polysaccharide, the polysaccharide lacking charged groups at a pH of between 6 and 8; and a nucleic acid delivery complex disposed within the active agent delivery structure. In an embodiment, the invention includes a material for medical applications including glycogen functionalized with coupling groups at a degree of substitution of between about 0.01 and 0.5. Other embodiments are also included herein.Type: GrantFiled: December 22, 2011Date of Patent: December 2, 2014Assignee: SurModics, Inc.Inventor: Joram Slager
-
Publication number: 20140350239Abstract: The present invention relates to a pharmaceutical composition for relieving pain in a joint disease, including a hyaluronic acid and a pharmaceutically acceptable carrier, in which the hyaluronic acid is cross-linked by cyclizing a double bond in the moiety of a cinnamic acid in a partially amidated hyaluronic acid represented by Formula (1): [Ar—CH?CH—COO—(CH2)n-NH-]m-HA, to form a cycloubutane ring, in which Ar represents an optionally substituted phenyl group, n represents an integer of 2 or 3, HA represents a carboxy residue of the hyaluronic acid, and m represents an amidation ratio of the hyaluronic acid to the total carboxyl group and is in the range of 3 to 50% relative to the total carboxyl group. The pharmaceutical composition of the present invention is an intra-articular formulation that exerts rapid analgesic effects after administration, and shows extremely long durable effects for a human joint disease with only a single administration rather than multiple administrations of a conventional way.Type: ApplicationFiled: August 5, 2014Publication date: November 27, 2014Inventors: Hiroyuki Hosokawa, Sooyeol Lim, Junko Oda
-
Publication number: 20140341934Abstract: The invention is directed to a process for extracting materials from biological material, which process is characterized in that the naturally occurring biological material is treated with an extractant consisting of a deep eutectic solvent of natural origin or a an ionic liquid of natural origin to produce a biological extract of natural origin dissolved in the said solvent or ionic liquid.Type: ApplicationFiled: August 5, 2014Publication date: November 20, 2014Inventors: Jacob van Spronsen, Geert-Jan Witkamp, Frank Hollman, Young Hae Choi, Robert Verpoorte
-
Publication number: 20140330005Abstract: A composition includes a polysaccharide at least one retinoid linked to at least one monosaccharide subunit of the polysaccharide with a covalent linkage. The linkage being degradable by hydrolysis during digestion of the composition to provide controlled, delayed, and/or sustained delivery of the at least one retinoid upon enteral administration of the composition to a subject.Type: ApplicationFiled: November 28, 2012Publication date: November 6, 2014Inventors: Songqi Gao, Krzysztof Palczewski, Zheng-Rong Lu
-
Patent number: 8877243Abstract: A process for making cross-linked polysaccharide gels, particularly cross-linked hyaluronic acid gels, under basic conditions. The resulting gels possess improved degradation characteristics, and are useful in a variety of medical and cosmetic applications.Type: GrantFiled: December 26, 2013Date of Patent: November 4, 2014Assignee: Ultraceuticals R&D Pty., Ltd.Inventors: Simone Charlotte Vonwiller, Geoffrey Kenneth Heber
-
Publication number: 20140322273Abstract: Provided is a strain of exopolysaccharide-secreting Lactobacillus plantarum and an application thereof. The deposit number of the strain is CGMCC No. 5222. The strain differs from other strains of Lactobacillus plantarum in the amount of exopolysaccharide secreted, has unique physiological and biochemical characteristics and genetic background, and is a newly isolated and identified strain of Lactobacillus plantarum.Type: ApplicationFiled: April 25, 2012Publication date: October 30, 2014Applicant: BRIGHT DAIRY & FOOD CO., LTD.Inventors: Lianzhong Ai, Benheng Guo, Kejie Sun, Wei Chen, Hao Zhang, Li Shao, Zhengjun Wu, Wanyi Chen, Feng Hang
-
Patent number: 8871740Abstract: The present invention relates to a composition including a mix of a polysaccharides having: 15% to 50% of glucoside linkages 1-6; a reducing sugar content of less than 20%; a polymolecularity index of less than 5; an average molecular weight with number Mn of less than 4500 g/mole and at least one active agent for treating stress, anxiety and depressive behavior, sleep disorders, obsessive-compulsive disorder, bulimia and epilepsy in humans or animals. The present invention also relates to the use of the polysaccharide for treating stress, anxiety or depressive behavior, sleep disorders, obsessive-compulsive disorder, bulimia and epilepsy in humans or animals.Type: GrantFiled: December 23, 2010Date of Patent: October 28, 2014Assignee: Roquette FreresInventors: Laetitia Guerin-Deremaux, Daniel Wils
-
Patent number: 8871923Abstract: The present invention generally relates to new plant elicitor compositions, and the use of these compositions in agricultural applications, more particularly to protect plants against (infection by) plant pathogens and the corresponding methods of, and uses in, the protection of plants and crops by application of these compositions.Type: GrantFiled: January 24, 2012Date of Patent: October 28, 2014Assignee: FYTOFEND S.A.Inventors: Raffaele Buonatesta, Géraldine Van Aubel, Pierre Van Cutsem
-
Patent number: 8871925Abstract: Aspects of the invention provide compositions for use in the treatment galectin-dependent diseases. In particular, compositions comprising a selectively depolymerized, branched galactoarabino-rhamnogalacturonate whose backbone is predominantly comprised of 1,4-linked galacturonic acid (GalA) moieties, with a lesser backbone composition of alternating 1,4-linked GalA and 1,2-linked rhamnose (Rha), which in-turn is linked to any number of side chains, including predominantly 1,4-b-D-galactose (Gal) and 1,5-a-L-arabinose (Ara) residues.Type: GrantFiled: September 14, 2012Date of Patent: October 28, 2014Assignee: Galectin Therapeutics Inc.Inventors: Eliezer Zomer, Peter G. Traber, Anatole A. Klyosov, Elena Chekhova
-
Publication number: 20140315814Abstract: The invention concerns a pentasaccharide compound of formula (I) and the salts thereof. The invention also concerns a pharmaceutical composition comprising the synthetic pentasaccharide compound of formula (I) and its salts. The invention further concerns these compounds for use as a medicament, and in particular intended to treat blood clotting disorders, to prevent ischaemia reperfusion injury associated with solid organ transplantation, or to reduce the risk of blood clotting in an extracorporeal blood circuit during cardiac surgery, extracorporeal membrane oxygenation, or during circulatory assistance such as artificial heart.Type: ApplicationFiled: June 18, 2012Publication date: October 23, 2014Applicant: CARBOMIMETICSInventors: Ahmed El Hadri, Maurice Petitou
-
Publication number: 20140314813Abstract: A novel lipoteichoic acid (LTA) was isolated from C. difficile, the structure of which is illustrated below wherein n is an integer between 1 and 20, R3 and R4 are independently selected from C 14:0, C 16:0, C 16:1, C 18:0 or C18:1 fatty acid or any combination thereof wherein one of COR3 or COR4 may be replaced by H. Further described are conjugates comprising the novel LTA and vaccines produced using the isolated LTA and the LTA conjugates. The invention also encompasses methods of conferring immunity against C. difficile comprising administering a vaccine of the invention, and methods of detecting C. difficile using the isolated LTA of the invention.Type: ApplicationFiled: November 16, 2012Publication date: October 23, 2014Applicant: National Research Council of CanadaInventors: Christopher Reid, Susan M. Logan, Evguenii Vinogradov, Andrew Cox, Jean-Robert Brisson
-
Publication number: 20140315308Abstract: The present invention provides a neutralized glucomannan scaffold capable of promoting cell growth and suitable for three-dimensional tissue culture and engineering. The present invention also provides methods for making and degrading the neutralized glucomannan scaffold. The present invention further provides a method of growing cells on a neutralized glucomannan scaffold.Type: ApplicationFiled: November 29, 2012Publication date: October 23, 2014Inventor: C. Chang I. Lee
-
Patent number: 8865241Abstract: The invention relates to mutant strains of the genus Sphingomonas which have a mutation in at least one gene encoding a protein involved in polyhydroxybutyrate (“PHB”) synthesis that allows the mutant strains to produce PHB-deficient Sphingans. The invention is also directed to a process for preparing a clarified Sphingan solution comprising heating aqueous Sphingan solution, in particular PHB-deficient Sphingan solution, to a clarification temperature of about 30° C. to about 70° C., and treating the solution with a clarification agent and enzymes. In addition, the invention is directed to a food or industrial product comprising a PHB-deficient and/or clarified Sphingan. One particular embodiment of the invention is directed to a clarified, PHB-deficient high-acyl gellan and the processes of making thereof.Type: GrantFiled: September 29, 2010Date of Patent: October 21, 2014Assignee: CP Kelco U.S., Inc.Inventors: Stan Bower, Ellen Burke, Nancy E. Harding, Yamini N. Patel, J. Carrie Schneider, Dagmar Meissner, Neil A. Morrison, Ralph Bezanson
-
Patent number: 8865681Abstract: In one embodiment, the invention provides a method of treating, reducing the incidence, reducing the severity or pathogenesis of an eye disease or disorder in a subject, including, inter alia, retinal detachment, macular degeneration, glaucoma or retinopathy, comprising the step of administering an effective amount of a lipid or phospholipid moiety bound optionally via a spacer to a physiologically acceptable monomer, dimer, oligomer, or polymer via an ester or amide bond, and/or a pharmaceutically acceptable salt or a pharmaceutical product thereof. This invention also provides a contact lens solution comprising a lipid or phospholipid moiety bound optionally via a spacer to a physiologically acceptable monomer, dimer, oligomer, or polymer via an ester or amide bond, and/or a pharmaceutically acceptable salt or a pharmaceutical product thereof.Type: GrantFiled: November 14, 2007Date of Patent: October 21, 2014Assignee: Yissum Research Development Company of the Hebrew Unitersity of JerusalemInventors: Saul Yedgar, Yuval Cohen
-
Patent number: 8865678Abstract: Universal sensory structurants and compositions comprising the same are described. The universal sensory structurants comprise polysaccharide carbohydrate having at least about 75% by weight amylopectin and the polysaccharide carbohydrate has been treated and swollen with a solvent comprising hydroxylated polymer comprising less than about 100 silane repeat units.Type: GrantFiled: October 8, 2008Date of Patent: October 21, 2014Assignee: Conopco, Inc.Inventor: Jack Polonka
-
Publication number: 20140309414Abstract: This invention relates to a field of pharmaceutical chemistry, relates to a process of extracting high water soluble polysaccharides from higher plants or fungi. The present invention discloses a process of extracting higher plants and fungi polysaccharides based on a microwave chemistry method, comprising: putting the residue or pulverized higher plants and fungi after being degreased by an organic solvent into a microwave reaction chamber to react with an acid solution; and then distilling to remove excess acid or washing with organic solvent to remove the acid; adding water solution for extraction, subjecting the extracting solution after concentration to alcohol precipitation, separating precipitates aka polysaccharides therefrom. The present invention has significant advantages like fast processing rate, high polysaccharides yield, low organic acid consumption and efficient and easy to recycle, low water consumption, low power consumption, etc.Type: ApplicationFiled: November 1, 2012Publication date: October 16, 2014Inventors: Jinsong Zhang, Mingtian Li, Zhiyu Liu, Lei Xu
-
Publication number: 20140308426Abstract: [Problem] The purpose of the present invention is to provide a natural polymeric emulsifier improved in so-called “emulsifying power”, said natural polymeric emulsifier being capable of forming, even by the addition thereof in a small amount, an oil-in-water emulsion which has a small emulsified particle diameter and a uniform particle size distribution and which rarely suffers from the aggregation or coalescence of emulsified particles even when has undergone heating, long-term storage, aging or the like. [Solution] The purpose can be achieved by using water-soluble soybean polysaccharides which have a methyl ester content of 30% or below relative to the uronic acids and an acetate content of 1 wt % or higher in terms of free acetic acid and relative to the water-soluble soybean polysaccharides.Type: ApplicationFiled: October 18, 2012Publication date: October 16, 2014Applicant: Fuji Oil Company LimitedInventors: Yasuhiko Yoshida, Minami Sato, Akihiro Nakamura
-
Publication number: 20140308272Abstract: According to the present invention, treatment of prion protein related diseases, and in particular cancer tumours, is effected by providing to a subject in need thereof a therapeutically effective amount of an agent capable of modulating binding of a prion protein and/or a prion-like protein to a disease related GAG and/or HSPG.Type: ApplicationFiled: January 17, 2014Publication date: October 16, 2014Applicant: Sylvan Pharmaceuticals Pty, Ltd.Inventors: John Fergus McEwan, David Cullis-Hill, Martin Lyndale Windsor
-
Patent number: 8859759Abstract: Particulate ?-glucan is solubilized at elevated pressure and temperature to form particulate-soluble ?-glucan. The particulate-soluble ?-glucan is capable of being dried to a powder form and subsequently re-solubilized.Type: GrantFiled: April 24, 2013Date of Patent: October 14, 2014Assignee: Biothera, Inc.Inventor: Donald J. Cox
-
Patent number: 8858917Abstract: Formulations have been developed for pulmonary delivery to treat or reduce the infectivity of diseases such as vital infections, especially tuberculosis, SARS, influenza and respiratory synticial virus in humans and hoof and mouth disease in animals. Formulations for pulmonary administration include a material that significantly alters physical properties such as surface tension and surface elasticity of lung mucus lining fluid, which may be a surfactant and, optionally, a carrier. The formulation may be administered as a powder where the particles consist basically of the material altering surface tension. The carrier may be a solution, such as an alcohol, although an aqueous solution may be utilized, or a material mixed with the material altering surface tension to form particles.Type: GrantFiled: January 9, 2009Date of Patent: October 14, 2014Assignee: President and Fellows of Harvard CollegeInventors: David A. Edwards, Howard A. Stone
-
Patent number: 8858955Abstract: The present application discloses a method for making an immunogenic composition comprising an improved way of conducting saccharide-protein conjugation reactions using carbodiimide condensation chemistry. Depending on the nature of the saccharide or protein carrier involved, the quality of the conjugate may be improved by adding one of the reaction components slowly to the reaction mixture. In addition, the conjugate is mixed with a staphylococcal antigen. Immunogenic compositions are further provided comprising the saccharide-protein conjugates made by the methods disclosed.Type: GrantFiled: January 2, 2008Date of Patent: October 14, 2014Assignee: GlaxoSmithKline Biologicals s.a.Inventors: Ralph Leon Biemans, Pierre Duvivier
-
Publication number: 20140303359Abstract: Disclosed is a method for selective synthesis of 1,2-cis-?-linked glycosides which does not require the use of the specialized protecting group patterns normally employed to control diastereoselectivity. Thioglycoside acceptors can be used, permitting iterative oligosaccharide synthesis. The approach eliminates the need for lengthy syntheses of monosaccharides possessing highly specialized and unconventional protecting group patterns.Type: ApplicationFiled: April 8, 2014Publication date: October 9, 2014Applicant: Trustees of Tufts CollegeInventors: Clay S. Bennett, An-Hsiang Adam Chu
-
Publication number: 20140303116Abstract: A novel compound is disclosed, said compound comprising hyaluronic acid, optionally cross-linked, or an oligomer, optionally cross-linked, dimer or monomer thereof, which is salified or at least partially salified with carnosine, wherein the carnosine is in the form of an L- or D-enantiomer or a racemate; a process for producing this compound, its cosmetic and therapeutic use as well as pharmaceutical and cosmetic compositions containing the same are also disclosed.Type: ApplicationFiled: December 6, 2011Publication date: October 9, 2014Inventor: Gianfranco De Paoli Ambrosi
-
Publication number: 20140303365Abstract: The present invention provides methods for treating phytoglycogen-containing materials to generate phytoglycogen compositions with enhanced emulsification attribute. One method comprises contacting a phytoglycogen-containing material with at least one protease. The other method comprises heat treatment of a phytoglycogen-containing material, such as corn kernels. The two methods can be applied independently, or can be applied in combination. Applications of phytoglycogen compositions are also included.Type: ApplicationFiled: October 15, 2012Publication date: October 9, 2014Applicant: PHYTOPTION, LLCInventor: Jingmin Zhang
-
Publication number: 20140301995Abstract: The invention is based on a correlation observed between serotonin level and intestinal flora. The invention relates to a relative proportion of bifidobacteria in the intestine and in particular to a product increasing the ratio of bifidobacteria to Clostridia, to be used for raising the serotonin level. The invention also relates to a method for estimating a health risk associated with serotonin depletion by determining a relative proportion between bifidobacteria or Clostridia in the intestine or their ratio to one another. The invention further relates to a method for selecting a form of therapy for raising the serotonin level by determining a relative proportion between bifidobacteria or Clostridia in the intestine or their ratio to one another.Type: ApplicationFiled: October 12, 2012Publication date: October 9, 2014Inventors: Annika Mayra-Makinen, Eveliina Munukka
-
Publication number: 20140302510Abstract: The present invention relates to a method of diagnosis, prognostic or treatment of neurodegenerative diseases, in particular Alzheimer's disease.Type: ApplicationFiled: October 15, 2012Publication date: October 9, 2014Inventors: Dulce Papy-Garcia, Minh Bao Huynh, Nadia Soussi-Yanicostas, Rita Vozari, Fernando Sineriz, Constantin Yanicostas
-
Publication number: 20140296496Abstract: This invention relates to an extraction process of brown algae polysaccharides in a field of pharmaceutical chemistry. This invention particularly discloses a process of extracting brown algae polysaccharides based on a microwave chemistry method and brown algae polysaccharides obtained by said process. The process of the invention comprises: 1) putting pulverized brown algae powder into a microwave reaction chamber, adding acid solution to conduct reaction; optionally concentrating the mixer, and then washing with organic solvent to remove excess acid; conducting grading alcohol precipitation after water extract to obtain mannuronic acid rich fragment (M rich) algin, fucoidan and/or laminaran respectively; and adding an alkali solution to the brown algae residue to conduct alkaline digestion, filtering the residue off, adjusting pH of the filtrate to neutral, conducting alcohol precipitation to obtain guluronic acid rich fragment (G rich) algin precipitates.Type: ApplicationFiled: November 1, 2012Publication date: October 2, 2014Inventors: Jinsong Zhang, Mingtian Li, Zhiyu Liu, Lei Xu
-
Publication number: 20140294930Abstract: In alternative embodiments, the invention provides vaccines, pharmaceutical compounds and formulations for diagnosing, preventing, treating or ameliorating Group A Streptococcus (GAS), Group C Streptococcus (GCS), or Group A Streptococcus (GGS), infections, or other pathogenic Streptococcus infections. In alternative embodiments, the invention provides compositions such as diagnostic tests, assays, immunoassays and test strips, and methods, for detecting or diagnosing the presence of a Streptococcal infection, e.g., Group A Streptococcus (GAS), Group C Streptococcus (GCS), or Group A Streptococcus (GGS), infections, or other pathogenic Streptococcus infections.Type: ApplicationFiled: August 3, 2012Publication date: October 2, 2014Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Victor Nizet, Nina van Sorge
-
Publication number: 20140296354Abstract: Described herein are the one-pot synthesis and characterization of a library of low molecular weight peptoid compounds that are able to form gels at room temperature. The compounds are synthesized from biologically-based starting materials, are biocompatible, and are resistant to degradation by proteases and peptidases.Type: ApplicationFiled: April 1, 2014Publication date: October 2, 2014Applicant: OLD DOMINION UNIVERSITY RESEARCH FOUNDATIONInventors: Guijun WANG, Hari P. R. MANGUNURU